An observational study in Schizophrenia, sponsored by Sumitomo Pharma (Suzhou) Co., Ltd.. Completed at 7 sites in China. Per ClinicalTrials.gov, last updated 2024-04-18.
Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd. · Observational
It's a prospective, non-interventional, observational Post-marketing Surveillance..
It's a prospective, non-interventional, observational Post-marketing Surveillance, the aim of the surveillance is to observe the safety and overall effectiveness of Latuda® in the treatment of Chinese patients with schizophrenia for 12 weeks in real clinical practice, as well as the dose of Latuda® for monotherapy or combination therapy.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's enrollment of 3,192 is above the median of 178 across 491 observational studies indexed under Schizophrenia.
Browse Schizophrenia studies →Sumitomo Pharma (Suzhou) Co., Ltd. is the lead sponsor of 13 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Schizophrenia Patients who begin to receive Latuda®
Exclusion criteria:
Chinese schizophrenia patients who are receiving Latuda® in the real world
Drug: Lurasidone HCl
This is a non-interventional, observational study
Also known as: Latuda®
The incidence of Adverse Event
Adverse events
Time frame: week 12
The incidence of extrapyramidal symptom
Extrapyramidal Symptoms (EPS) are drug-induced movement disorders that accur due to antipsychotic blockade of the nigrostriatal dopamine tracts, including acute dystonia, akathisia, antipsychotic-induced parkinsonism, tardive dyskinesia (TD)
Time frame: baseline/ week 2-4/ week 6-8/ week 12
The incidence of akathisia
Akathisia is a side effect of antipsychotic drugs, presenting as restlessness, fidgeting of the legs, rocking, pacing, and the inability to sit or stand still.
Time frame: baseline/ week 2-4/ week 6-8/ week 12
the rate of use of extrapyramidal symptom treatment drugs
extrapyramidal symptom treatment drugs are medications to decrease extrapyramidal side effects
Time frame: baseline/ week 2-4/ week 6-8/ week 12
Changes in body weight at the end of treatment compared with baseline
Weight is measured on a scale
Time frame: baseline/ week 12
The overall Brief Psychiatric Rating Scale (BPRS) score change at the end of the treatment compared with the baseline
Brief Psychiatric Rating Scale (BPRS) is a generic scale developed to measure clinical change in patients with schizophrenia and which can be used as a global measure of psychopathology. Each of the 18 items are designed to represent a discrete symptom area. Items are rated on a 7-point Likert scale, from 1 = "not present" to 7 = "extremely severe", with scores ranging from 18 to 126 (achieved through summing the item scores).
Time frame: baseline/ week 2-4/ week 6-8/ week 12
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sumitomo Pharma (Suzhou) Co., Ltd.